药物性肝损伤糖皮质激素应用的时机与指征

肝脏 ›› 2020, Vol. 25 ›› Issue (7): 676-678.

药物性肝损伤糖皮质激素应用的时机与指征

李文庭, 杨亮, 何宏亮, 赵宗豪, 李宜

230001 合肥中国科学技术大学附属第一医院(安徽省立医院)感染科

收稿日期:2020-03-24 发布日期:2020-08-06
通讯作者: 李宜,Email: wtl9911002@163.com
基金资助:
安徽省自然科学基金 (1908085MH242)

Application of glucocorticosteroid in drug induced liver injury

LI Wen-ting, YANG Liang, HE Hong-liang, ZHAO Zong-hao, LI Yi

Department of Infectious Disease, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Anhui 230000, China

Received:2020-03-24 Published:2020-08-06
Contact: LI Yi, Email: wtl9911002@163.com

摘要/Abstract

摘要： 目的: 探索糖皮质激素治疗药物性肝损伤的时机与指征。方法: 回顾性分析了2018至2020年我科收治的药物性肝损伤患者33例,分析其人口特征、病因及临床表现。根据是否使用激素分为2组,观察组使用常规药物治疗,治疗组在常规治疗基础上加用糖皮质激素治疗, 比较两组患者及治疗组患者激素治疗前后患者肝功能变化,观察激素治疗的总体有效率及治疗期间不良反应的发生。结果: 对于无禁忌证的药物性肝损伤患者,特别是重度肝损伤患者,早期使用糖皮质激素的总体有效率明显高于治疗前(P<0.05),激素减量后肝功能无反跳,治疗期间无明显不良反应发生。结论: 对于药物性肝损伤患者,早期使用激素效果良好,且安全性高。

关键词: 糖皮质激素, 药物性肝损伤, 治疗

Abstract: Objective To investigate the indication and timing of glucocorticosteroid (GC) therapy for drug induced liver injury(DILI). Methods This study retrospectively analyzed the demographic characteristics, etiology and clinical manifestations of 33 patients with DILI in our hospital from 2018 to 2020. Patients were divided into 2 groups, 21 patients in control group received routine medical treatment, 12 patients in treatment group were given GC combined with routine medical treatment. The results of laboratory test including liver function were analyzed. Furthermore, the effective rate and side effects were also observed during the treatment. Results GC significantly improved the effective rate of therapy for DILI, especially severe liver injury. There was no rebound of liver function while tapering GC or GC related side effects during the treatment. Conclusion It is safe and efficient to use GC in early stage of DILI.

Key words: lucocorticosteroid, Acute, Severe liver injury, Drug-induced liver injury, Treatment

李文庭, 杨亮, 何宏亮, 赵宗豪, 李宜. 药物性肝损伤糖皮质激素应用的时机与指征[J]. 肝脏, 2020, 25(7): 676-678.

LI Wen-ting, YANG Liang, HE Hong-liang, ZHAO Zong-hao, LI Yi. Application of glucocorticosteroid in drug induced liver injury[J]. Chinese Hepatolgy, 2020, 25(7): 676-678.

参考文献

[1] 中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南. 肝脏, 2015, 20: 750-767.
[2] 魏巍,曹武奎,李谦. 糖皮质激素在肝功能衰竭中治疗作用的研究进展. 肝脏, 2015,20: 257-259.
[3] 王炳元.重症酒精性肝炎需要关注的几个问题.实用肝脏病杂志, 2014, 17:3-4.
[4] Gravbrot N, Sundararajan S. Severe drug-induced liver injury from combination encorafenib/binimetinib. Case Rep Oncol Med,2019,2019:3051945.
[5] Giordano C, Rivas J, Zervos X. An update on treatment of drug-induced liver injury. J Clin Transl Hepatol,2014, 2:74-79.
[6] Shen T, Liu Y, Shang J, Incidence and etiology of drug-induced liver injury in mainland China. Gastroenterology,2019, 156:2230-2241.
[7] Xiao X, Tang J, Mao Y,et al. Guidance for the clinical evaluation of traditional Chinese medicine-induced liver injuryIssued by China Food and Drug Administration. Acta Pharm Sin B,2019, 9:648-658.
[8] 朱孝雷,吴静. 58 例药物性肝功能损害案例的不良反应分析及其对策. 抗感染药学,2019, 16:641-643.
[9] Khoury T, Rmeileh AA, Yosha L, et al. Drug induced liver injury: review with a focus on genetic factors, tissue diagnosis, and treatment options. J Clin Transl Hepatol,2015, 3:99-108.
[10] Chin M, Levy RD, Yoshida EM, et al. Sitaxsentan-induced acute severe hepatitis treated with glucocorticoid therapy. Can Respir J, 2012, 19: e1-e2.
[11] 周超, 罗生强, 宫嫚, 等. 糖皮质激素在常见肝病治疗中的应用. 胃肠病学和肝病学杂志, 2015, 24: 15-17.
[12] 张玉果, 赵素贤, 李文聪, 等. 糖皮质激素治疗重症药物性肝损伤的临床研究. 肝脏, 2017, 22: 214-218.
[13] 黄春洋,单晶,廖慧钰,等. 甲基强的松龙治疗药物性肝损伤患者临床及实验室特点分析.实用肝脏病杂志, 2019, 22: 208-211.
[14] 贾长河,袁媛,刘博伟,等. 小剂量糖皮质激素治疗胆汁瘀积型药物性肝炎.中国实用医刊, 2011, 38: 68-71.
[15] Weber S, Benesic A, Rotter I, et al. Early ALT response to corticosteroid treatment distinguishes idiosyncratic drug-induced liver injury from autoimmune hepatitis. Liver Int,2019, 39:1906-1917.